Recently, Si et al. disclosed that silibinin treatment promoted mitochondrial fusion by suppressing the expression of DRP1 and enhancing the expression of Mfn1, Mfn2, and OPA1, leading to attenuated migration and invasion of breast cancer cells [94]. Here, OPA1 is linked to breast carcinoma.